TY - JOUR
T1 - Management of patients with newly diagnosed chronic myeloid leukemia
T2 - Opportunities and challenges
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - O'Brien, Susan
AU - Rios, Mary Beth
AU - Giles, Francis
AU - Kantarjian, Hagop
N1 - Funding Information:
Dr Jabbour is a member of the Speaker’s Bureau for Novartis Oncology and Bristol-Myers Squibb. Dr Cortes has received research support from Breakthrough Therapeutics, Novartis Oncology, Johnson & Johnson, Schering-Plough, Bristol-Myers Squibb, and ChemGenex Pharmaceuticals. He is also a member of the Speaker’s Bureau for Novartis Oncology and Celgene. Dr O’Brien has received research support from Genentech BioOncol, Berlex, and Biogen Idec. Dr Rios is a member of the Speaker’s Bureau for Bristol-Myers Squibb and has received other remuneration from Novartis. Dr Giles has received research support from Novartis Oncology, Bristol-Myers Squibb, Merck, SGX Pharmaceuticals, Amgen, and Pfizer. Dr Kantarjian has received research support from Bristol-Myers Squibb, Novartis Oncology, and MGI Pharma. This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of nilotinib, p210 multipeptide vaccine, nonpeptide PR1 vaccine, and a heat-shock protein–70–based vaccine in the treatment of CML.
PY - 2007/3
Y1 - 2007/3
N2 - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.
AB - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.
KW - Cytogenetic response
KW - Immunotherapy
KW - Myeloid blast crisis
KW - Myelosuppression
KW - Stem cell transplantation
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=34247869894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247869894&partnerID=8YFLogxK
U2 - 10.3816/CLM.2007.s.002
DO - 10.3816/CLM.2007.s.002
M3 - Article
C2 - 17382013
AN - SCOPUS:34247869894
SN - 1557-9190
VL - 7
SP - S51-S57
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
IS - SUPPL. 2
ER -